Incidence of HBV Reactivation in Psoriasis Patients Undergoing Cytokine Inhibitor Therapy: A Single-Center Study and Systematic Review with a Meta-Analysis
Viruses · 2024
DOI: 10.3390/v17010042 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Viruses, 2024. Verfasst von Meng Hsuan Kuo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi 622, Taiwan. Hauptthemen laut MEDLINE: Psoriasis, Hepatitis B virus, Virus Activation, Hepatitis B. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation.
Abstract (Originalsprache)
Background
Psoriasis patients who are seropositive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) face an elevated risk of hepatitis B virus reactivation (HBVr) when treated with cytokine inhibitors. This study aims to elucidate the risk in this population.
Methods
A retrospective chart review was conducted to assess the risk of HBVr in 73 psoriasis patients treated with cytokine inhibitors from 2013 to 2023. Additionally, a systematic review and meta-analysis were performed, pooling data from 10 studies (including our cohort) and adhering to PRISMA guidelines. Statistical heterogeneity was assessed using the I2 statistic, and pooled proportions were calculated using a random effects model.
Results
No HBVr cases were observed among the 11 HBsAg+ patients in the cohort. However, two of the sixty-two (3.2%) HBsAg−/HBcAb+ patients experienced reactivation during therapy, with outcomes ranging from spontaneous recovery in one case to death from hepatic failure despite antiviral treatment in the other. The meta-analysis, pooling data from 10 studies, revealed a reactivation rate of 21.2% (95% CI: 9.4–41.0%) in HBsAg+ patients without prophylaxis and 4.4% (95% CI: 2.2–8.7%) in HBsAg−/HBcAb+ patients.
Conclusion
Antiviral prophylaxis is essential for HBsAg+ patients receiving cytokine inhibitors, given the high risk of reactivation. Despite the lower risk for HBsAg−/HBcAb+ patients, the potential severity of outcomes demands careful monitoring and timely action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi 622, Taiwan.
- School of Medicine, Tzuchi University, Hualien 970, Taiwan.
- Division of Gastroenterology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi 622, Taiwan.
- Division of Rheumatology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi 622, Taiwan.
ORCID-Profile: Sz-Tsan Wang, Chih-Wei Tseng
Förderung
- Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Zitieren
APA
Kuo, M. H., Ko, P. H., Wang, S. T., & Tseng, C. W. (2024). Incidence of HBV Reactivation in Psoriasis Patients Undergoing Cytokine Inhibitor Therapy: A Single-Center Study and Systematic Review with a Meta-Analysis. Viruses. https://doi.org/10.3390/v17010042
Vancouver
Kuo MH, Ko PH, Wang ST, Tseng CW. Incidence of HBV Reactivation in Psoriasis Patients Undergoing Cytokine Inhibitor Therapy: A Single-Center Study and Systematic Review with a Meta-Analysis. Viruses. 2024. doi:10.3390/v17010042
BibTeX
@article{Kuo2024,
author = {Kuo, Meng Hsuan and Ko, Ping-Hung and Wang, Sz-Tsan and Tseng, Chih-Wei},
title = {Incidence of HBV Reactivation in Psoriasis Patients Undergoing Cytokine Inhibitor Therapy: A Single-Center Study and Systematic Review with a Meta-Analysis},
journal = {Viruses},
year = {2024},
doi = {10.3390/v17010042}
}
EUVIMED